Search Within

GME, Medicine

Formats
  1. Meeting Abstract (682)
  2. Journal Article (537)
  3. Review (141)
  4. Editorial (63)
  5. Research Letter (56)
  6. Correspondence (24)
  7. Miscellaneous (6)
  8. Book Section (5)
  9. Conference Paper (4)
  10. Guidelines (3)
Groups
  1. Graduate Medical Education (1521)
  2. Department of Medicine (1195)
  3. Hematology-Oncology Fellows (994)
  4. Hematologic Malignancies, Division of (702)
  5. Solid Tumor Oncology Division (612)
  6. Weinberg Fellows (569)

More Groups

People
  1. Kylee Maclachlan (143)
  2. Gunjan Shah (135)
  3. Michael Scordo (131)
  4. Sergio Giralt (123)
  5. Saad Usmani (120)
  6. Alexander Lesokhin (111)

More People

Years
  1. 2025 (110)
  2. 2024 (365)
  3. 2023 (404)
  4. 2022 (323)
  5. 2021 (154)
  6. 2020 (73)

More Years

Publications
  1. Blood (249)
  2. Journal of Clinical Oncology (218)
  3. Clinical Lymphoma, Myeloma and Leukemia (46)
  4. Clinical Cancer Research (42)
  5. Annals of Oncology (37)
  6. Cancer Research (34)

More Publications

Publishers
  1. American Society of Hematology (285)
  2. American Society of Clinical Oncology (250)
  3. Elsevier Inc. (199)
  4. Nature Publishing Group (105)
  5. American Association for Cancer Research (100)
  6. Oxford University Press (69)

More Publishers

Results (1521)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Genomic landscape of IgM MGUS and stable versus progressive asymptomatic Waldenström macroglobulinemia patients
    Meeting Abstract

    Bagratuni, T.; Theologi, O.; Vlachos, C.; Aktypi, F.; Maclachlan, K.; Kollias, I.; Mavrianou-Koutsoukou, N.; Liacos, C.; Papadimou, A.; Taouxi, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma
    Meeting Abstract

    McPherson, A.; Maclachlan, K.; Myers, M.; Satas, G.; Garcés, J. J.; Lee, H.; Bahlis, N. J.; Usmani, S.; Shah, S.; Maura, F.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save